Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non–Small Cell Lung Cancer

Uhlig, Johannes; Case, Meaghan Dendy; Blasberg, Justin D.; Boffa, Daniel J.; Chiang, Anne C.; Gettinger, Scott

doi:10.1001/jamanetworkopen.2019.9702

Cited by 42 publications

(22 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Prior studies have reported beneficial outcomes of multimodal therapy (combination of local and systemic therapy) [ 26 ]. In a study of NCDB data of patients with stage IV NSCLC, surgical resection plus systemic therapy or EBRT/thermal ablation plus systemic therapy was shown to be beneficial compared to systemic therapy alone [ 27 ]. Among the selected patients with limited metastases, benefits of local therapy in conjunction with systemic therapy have been observed [ 28 ].…”

Section: Discussionmentioning

confidence: 99%

Survival Outcomes with Photodynamic Therapy, Chemotherapy and Radiation in Patients with Stage III or Stage IV Non-Small Cell Lung Cancer

Chhatre

Vachani

Allison³

et al. 2021

Cancers

View full text Add to dashboard Cite

Data regarding the association between photodynamic therapy (PDT) and mortality in lung cancer patients are limited. We analyzed the association between PDT and mortality in patients with stage III or IV non-small cell lung cancer (NSCLC) using data from the National Cancer Database (NCDB) between 2004 and 2016. From the NCDB, we identified patients receiving laser ablation/cryosurgery or local tumor destruction/excision (which includes PDT). From Medicare and Medicaid claims between 2000 and 2013, we identified NSCLC patients receiving PDT and those receiving bronchoscopy, then used these to confirm the PDT treatment. From NCDB, we extracted NSCLC patients who received radiation with chemotherapy, radiation alone or chemotherapy alone. We used survival analysis to determine the association between PDT and mortality. Between 2004 and 2016, 457,556 NSCLC patients with stage III or stage IV were identified, of which 147 received PDT with radiation and chemotherapy, 227,629 received radiation with chemotherapy, 106,667 had radiation therapy alone and 122,193 received chemotherapy alone. Compared to the radiation alone group, the PDT group and radiation with chemotherapy group had lower hazard of mortality (50% and 53% lower, respectively). Among the NSCLC patients with stage III or stage IV disease, the addition of PDT to radiation therapy offers survival benefit over radiation therapy alone.

show abstract

Section: Discussionmentioning

confidence: 99%

Survival Outcomes with Photodynamic Therapy, Chemotherapy and Radiation in Patients with Stage III or Stage IV Non-Small Cell Lung Cancer

Chhatre

Vachani

Allison³

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Local therapy was independently associated with improved OS, particularly among patients without thoracic nodal disease or bone metastases, and with more than one metastatic site (54). In another retrospective study, OS benefit from the addition of local therapy was confined to T1-2, N0-1 squamous cell carcinoma patients with one metastasis (HR, 0.68; 95% CI, 0.57-0.80; P<0.001), whereas those with adenocarcinoma, T3-T4, N2-N3 and two or more metastases showed inferior OS compared to systemic therapy alone (55).…”

Section: Oligometastatic Diseasementioning

confidence: 99%

Multidisciplinary team care in advanced lung cancer

Kowalczyk

Jassem

2020

Transl Lung Cancer Res

View full text Add to dashboard Cite

Lung cancer is the most common cause of cancer mortality globally. A vast majority of lung cancer cases are diagnosed at advanced stages. Management of advanced lung cancer requires several diagnostic and therapeutic procedures provided by various specialists. To optimise the entire diagnostic and therapeutic process, a concept of care provided simultaneously by a multidisciplinary team (MDT) has been developed and implemented in specialised centres worldwide. Observational studies suggest that integrated and coordinated care increases adherence to clinical guidelines, significantly shortens the interval from diagnosis to treatment, and may increase survival and quality of life (QoL). Prospective studies are warranted to assess the real impact of MDT on treatment outcomes and to further refine this approach.

show abstract

“…In particular, EBRT becomes an effective treatment option for a subset of patients who are not candidates for surgical resection. 81 Generally, for intraocular metastasis, systemic therapy seems to have a lower local disease control rate (DCR) and a higher local recurrence rate when compared with local treatment. Intervention using local treatments helps to achieve higher response rates, while possibly also increasing local treatment-related complications.…”

Section: Targeted Therapymentioning

confidence: 99%

A Comprehensive Understanding of Choroidal Metastasis from Lung Cancer

Qu¹,

Liu²,

Zhu³

et al. 2021

OTT

View full text Add to dashboard Cite

The incidence of lung cancer with intraocular metastasis is low, of which choroidal metastasis is the most painful metastatic lesion. The clinical symptoms resulting from choroidal metastasis from lung cancer easily detected although they are rarely identified prior to the diagnosis of the primary malignancy. The quality of life of patients is inevitably impaired. Some lung cancer patients complain of ocular symptoms as the first manifestation of lung cancer. Early diagnosis and treatment can significantly overcome or delay the visual impairment and improve prognosis. The main therapeutic modalities include systemic and local treatments, while observation is also a treatment option. Currently, the feasibility and effectiveness of various treatment options are controversial worldwide. Herein, we summarize the underlying mechanisms, epidemiology, clinical features, auxiliary examinations, diagnosis, and recent treatment options for intraocular metastases.

show abstract

Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non–Small Cell Lung Cancer

Cited by 42 publications

References 38 publications

Survival Outcomes with Photodynamic Therapy, Chemotherapy and Radiation in Patients with Stage III or Stage IV Non-Small Cell Lung Cancer

Survival Outcomes with Photodynamic Therapy, Chemotherapy and Radiation in Patients with Stage III or Stage IV Non-Small Cell Lung Cancer

Multidisciplinary team care in advanced lung cancer

A Comprehensive Understanding of Choroidal Metastasis from Lung Cancer

Contact Info

Product

Resources

About